Abliva AB (publ) (NEVPF)
USD 0.04
(0.0%)
USD 0.04
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -5.64 Million USD | 10.17% |
| 2022 | -6.28 Million USD | -155.71% |
| 2021 | -2.45 Million USD | 66.83% |
| 2020 | -7.41 Million USD | -19.75% |
| 2019 | -6.19 Million USD | -111.52% |
| 2018 | -2.92 Million SEK | 17.34% |
| 2017 | -3.54 Million SEK | 65.5% |
| 2016 | -10.26 Million SEK | 10.47% |
| 2015 | -11.46 Million SEK | 76.93% |
| 2014 | -49.69 Million SEK | -24.27% |
| 2013 | -39.99 Million SEK | -7.57% |
| 2012 | -37.17 Million SEK | -190.56% |
| 2011 | -12.79 Million SEK | 53.9% |
| 2010 | -27.75 Million SEK | -921.94% |
| 2009 | -2.71 Million SEK | 66.23% |
| 2008 | -8.04 Million SEK | -2470.12% |
| 2007 | -312.88 Thousand SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -2.87 Million USD | 46.13% |
| 2024 Q2 | -4.22 Million USD | -46.06% |
| 2023 Q2 | -5.82 Million USD | -3.36% |
| 2023 Q4 | -5.64 Million USD | -6.6% |
| 2023 FY | -5.64 Million USD | 10.17% |
| 2023 Q3 | -5.3 Million USD | 9.07% |
| 2023 Q1 | -5.63 Million USD | 10.33% |
| 2022 Q1 | 36.42 Thousand SEK | 101.48% |
| 2022 FY | -6.28 Million USD | -155.71% |
| 2022 Q4 | -6.28 Million USD | 4.53% |
| 2022 Q3 | -6.58 Million USD | 49.96% |
| 2022 Q2 | -13.16 Million SEK | -36239.36% |
| 2021 Q1 | -5.5 Million SEK | 91.07% |
| 2021 Q2 | -11 Million SEK | -100.0% |
| 2021 Q3 | -7.19 Million SEK | 34.6% |
| 2021 Q4 | -2.45 Million SEK | 65.84% |
| 2021 FY | -2.45 Million USD | 66.83% |
| 2020 Q3 | -73.17 Million SEK | -5.95% |
| 2020 Q4 | -61.64 Million SEK | 15.76% |
| 2020 FY | -7.5 Million USD | -19.75% |
| 2020 Q1 | -29.52 Million SEK | 49.34% |
| 2020 Q2 | -69.07 Million SEK | -133.96% |
| 2019 Q2 | -99.07 Million SEK | 12.58% |
| 2019 FY | -6.19 Million USD | -111.52% |
| 2019 Q4 | -58.28 Million SEK | 26.94% |
| 2019 Q3 | -79.77 Million SEK | 19.49% |
| 2019 Q1 | -113.33 Million SEK | -336.74% |
| 2018 Q1 | -15.75 Million SEK | 45.65% |
| 2018 Q4 | -25.95 Million SEK | 32.37% |
| 2018 Q3 | -38.37 Million SEK | 26.06% |
| 2018 Q2 | -51.89 Million SEK | -229.35% |
| 2018 FY | -2.92 Million SEK | 17.34% |
| 2017 Q2 | -46.98 Million SEK | 30.18% |
| 2017 Q3 | -35.43 Million SEK | 24.58% |
| 2017 Q4 | -28.99 Million SEK | 18.18% |
| 2017 FY | -3.54 Million SEK | 65.5% |
| 2017 Q1 | -67.28 Million SEK | 27.84% |
| 2016 Q1 | -78.74 Million SEK | 18.53% |
| 2016 Q4 | -93.25 Million SEK | 17.4% |
| 2016 Q3 | -112.88 Million SEK | 14.66% |
| 2016 FY | -10.26 Million SEK | 10.47% |
| 2016 Q2 | -132.28 Million SEK | -67.98% |
| 2015 Q4 | -96.66 Million SEK | 17.36% |
| 2015 Q2 | -138.04 Million SEK | -31.81% |
| 2015 FY | -11.46 Million SEK | 76.93% |
| 2015 Q1 | -104.73 Million SEK | -110.74% |
| 2015 Q3 | -116.96 Million SEK | 15.27% |
| 2014 Q3 | -58.94 Million SEK | 20.89% |
| 2014 FY | -49.69 Million SEK | -24.27% |
| 2014 Q4 | -49.69 Million SEK | 15.69% |
| 2014 Q2 | -74.51 Million SEK | 23.26% |
| 2014 Q1 | -97.09 Million SEK | -142.79% |
| 2013 Q2 | -22.97 Million SEK | 17.13% |
| 2013 Q3 | -14.99 Million SEK | 34.72% |
| 2013 Q4 | -39.99 Million SEK | -166.7% |
| 2013 FY | -39.99 Million SEK | -7.57% |
| 2013 Q1 | -27.71 Million SEK | 25.44% |
| 2012 Q4 | -37.17 Million SEK | 14.66% |
| 2012 Q1 | -9.96 Million SEK | 22.15% |
| 2012 Q2 | -49.42 Million SEK | -396.16% |
| 2012 FY | -37.17 Million SEK | -190.56% |
| 2012 Q3 | -43.56 Million SEK | 11.85% |
| 2011 FY | -12.79 Million SEK | 53.9% |
| 2011 Q1 | -23.8 Million SEK | 14.24% |
| 2011 Q2 | -19.89 Million SEK | 16.4% |
| 2011 Q3 | -15.81 Million SEK | 20.5% |
| 2011 Q4 | -12.79 Million SEK | 19.11% |
| 2010 Q4 | -27.75 Million SEK | 7.25% |
| 2010 Q3 | -29.92 Million SEK | 9.59% |
| 2010 Q1 | 1.32 Million SEK | 148.64% |
| 2010 Q2 | -33.09 Million SEK | -2605.61% |
| 2010 FY | -27.75 Million SEK | -921.94% |
| 2009 Q4 | -2.71 Million SEK | 0.0% |
| 2009 FY | -2.71 Million SEK | 66.23% |
| 2008 FY | -8.04 Million SEK | -2470.12% |
| 2007 FY | -312.88 Thousand SEK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 135.841% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 237.192% |
| SQZ Biotechnologies Company | -36.23 Million USD | 84.41% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 113.202% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 10.388% |
| Mesoblast Limited | 55.85 Million USD | 110.114% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | 709.326% |
| Genus plc | 190.6 Million USD | 102.964% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 352.684% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | 565.413% |
| Marizyme, Inc. | 18.56 Million USD | 130.425% |
| ContraFect Corporation | -6.02 Million USD | 6.246% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | 930.822% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | 4296.101% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | 588.96% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 351.963% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 202.684% |
| MultiCell Technologies, Inc. | 90.04 USD | 6274631.319% |
| Accustem Sciences Inc. | -733.97 Thousand USD | -669.722% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 143.64% |
| EV Biologics, Inc. | 1.36 Million USD | 512.99% |
| Q BioMed Inc. | 4.06 Million USD | 239.152% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 118.491% |
| Neon Bloom, Inc. | 622.36 Thousand USD | 1007.763% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | 660.633% |
| Biomind Labs Inc. | 711.4 Thousand USD | 894.148% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 109.8 Million USD | 105.145% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 144.115% |
| Skye Bioscience, Inc. | -5.72 Million USD | 1.255% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | 756.745% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | 4141.078% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 200.022% |
| IMV Inc. | 7.67 Million USD | 173.653% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | 28537.046% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 356.568% |
| GB Sciences, Inc. | 1.74 Million USD | 423.329% |
| Alpha Cognition Inc. | -183.78 Thousand USD | -2973.97% |
| HST Global, Inc. | 96.79 Thousand USD | 5936.773% |
| CSL Limited | 10.52 Billion USD | 100.054% |
| Halberd Corporation | 144.72 Thousand USD | 4003.779% |
| Enzolytics Inc. | 981.65 Thousand USD | 675.516% |
| Resverlogix Corp. | 6.45 Million USD | 187.577% |
| Affymax, Inc. | -5.59 Million USD | -0.94% |
| SYBLEU INC | 473.71 Thousand USD | 1292.616% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | -739.352% |
| argenx SE | -2.02 Billion USD | 99.722% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 113.007% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 87.983% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 308.578% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 36.09% |
| AVAX Technologies, Inc. | -5.9 Million USD | 4.296% |
| Zenith Capital Corp. | 10.06 Thousand USD | 56236.606% |
| Genscript Biotech Corporation | -1.06 Billion USD | 99.468% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | 2918.706% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 336.777% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | 3534.212% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 109.331% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 382.565% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -2.57 Million USD | -119.826% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 1670.595% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 127.863% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | -30741.729% |
| BioStem Technologies, Inc. | 4.47 Million USD | 226.332% |
| ONE Bio Corp. | 9.04 Million USD | 162.495% |
| Reve Technologies, Inc. | 201.25 Thousand USD | 2907.193% |
| Burzynski Research Institute, Inc. | -1310.00 USD | -431166.26% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | 2839.633% |
| Agentix Corp. | 37.63 Thousand USD | 15113.122% |
| LadRx Corporation | -2.03 Million USD | -177.421% |
| Cell Source, Inc. | 9.23 Million USD | 161.196% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | -27583.203% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 989.465% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 989.465% |
| NovAccess Global Inc. | 2.17 Million USD | 359.338% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 179.898% |
| Itoco Inc. | 228.3 Thousand USD | 2574.579% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | 4254.445% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 213.972% |
| Kadimastem Ltd | -253.1 Thousand USD | -2132.139% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 1505.898% |
| CytoDyn Inc. | 20.26 Million USD | 127.883% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | -873097.527% |
| Mobile Lads Corp. | 484.23 Thousand USD | 1266.711% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | -60855.77% |
| Qrons Inc. | 351.42 Thousand USD | 1707.614% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 173.314% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | -2163.275% |
| Rebus Holdings, Inc. | 305 Thousand USD | 1952.324% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 226.757% |
| International Stem Cell Corporation | 2.59 Million USD | 318.131% |
| Bioxytran, Inc. | 1.89 Million USD | 397.517% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | 9151.941% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 359.048% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 264.519% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 166.054% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | 772.6 Thousand USD | 831.237% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | -351.967% |
| Neutra Corp. | 52.18 Thousand USD | 10925.662% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | -126.982% |
| PureTech Health plc | -167.19 Million USD | 96.621% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | -2206.821% |
| IXICO plc | -4.44 Million USD | -27.112% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 142.738% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 110.3% |
| CSL Limited | 10.52 Billion USD | 100.054% |
| Cellectis S.A. | -43.81 Million USD | 87.107% |